The dominant theory about antibodies is that they directly target and kill disease-causing organisms. In a surprising twist, researchers from the Albert Einstein College of Medicine have discovered that certain antibodies to Streptococcus pneumoniae actually trick the bacteria into killing each other.
Pneumococcal vaccines currently in use today target the pneumococcal capsular polysaccharide (PPS), a sort of armor that surrounds the bacterial cell, protecting it from destruction. Current thought hold that PPS-binding antibodies protect against pneumococcus by inducing opsonic killing, a process in which pathogens are coated with a substance called opsonin, marking the pathogen out for destruction by the immune system.
While such antibodies are an important part of how pneumococcal vaccines protect against disease, there are PPS-specific antibodies that do not promote opsonic killing but are protective nonetheless. In the study, Masahide Yano and his colleagues identify one of mechanisms these non-opsonic antibodies use. They increase the rate of communication between the bacterial cells as well as competence-induced killing, or fratricide, where the bacteria naturally kill each other off because of overconcentration.
"These findings reveal a novel, previously unsuspected mechanism by which certain PPS-specific antibodies exert a direct effect on pneumococcal biology that has broad implications for bacterial clearance, genetic exchange and antibody immunity to pneumococcus," says Yano.
The resesarch was published in mBio.
Managerial Challenges: Setting Boundaries and Priorities in the Workplace
May 3rd 2024Maintaining boundaries can be challenging in a culture of overwork. In this installment of Dear Helpdesk, learn how to communicate effectively with your boss, prioritize your values, and safeguard your work-life balance.
Comprehensive Guide to Lymphedema: Causes, Prevention, and Management Strategies
May 3rd 2024Lymphedema, a chronic condition often stemming from cancer treatments, leads to tissue swelling. Early detection through surveillance programs and proper skincare can prevent complications like infections.
Advancing Viral Disease Treatment of Recurrent Genital Herpes, Hepatitis B and D Viruses
May 2nd 2024Health care has an unmet need for the treatment of herpesviruses, hepatitis B, and hepatitis D, which would enhance patient outcomes. What should be done, and what challenges do companies that are trying to develop treatments face?